Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program-Reference-Cited by-同舟云学术

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program

Published:2016-05-30 Issue:10 Volume:63 Page:1744-1752
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Kang Min H.¹,Reynolds C. Patrick¹,Kolb E. Anders²,Gorlick Richard³,Carol Hernan⁴,Lock Richard⁴,Keir Stephen T.⁵,Maris John M.⁶,Wu Jianwrong⁷,Lyalin Dmitry⁸,Kurmasheva Raushan T.⁸,Houghton Peter J.⁸,Smith Malcolm A.⁹

Affiliation:

1. Cancer Center; Texas Tech University Health Sciences Center; Lubbock Texas

2. A.I. duPont Hospital for Children; Wilmington Delaware

3. The Children's Hospital at Montefiore; Bronx New York

4. Children's Cancer Institute Australia for Medical Research; Randwick NSW Australia

5. Duke University Medical Center; Durham North Carolina

6. Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute; Philadelphia Pennsylvania

7. St. Jude Children's Research Hospital; Memphis Tennessee

8. Nationwide Children's Hospital; Columbus Ohio

9. Cancer Therapy Evaluation Program; NCI; Bethesda Maryland

Funder

National Cancer Institute

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference41 articles.

1. p53 in health and disease;Vousden;Nat Rev Mol Cell Biol,2007

2. p53 the cellular gatekeeper for growth and division;Levine;Cell,1997